A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT05361174
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Unresectable Melanoma
- Metastatic Melanoma
- Stage III Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Iovance Biotherapeutics, Inc.
- Last updated on ClinicalTrials.gov
- June 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- The Angeles Clinic and Research Institute · Los Angeles, CA
Florida · 3
- Sylvester Comprehensive Cancer Center · Miami, FL
- Orlando Health Cancer Institute · Orlando, FL
- Moffitt Cancer Center · Tampa, FL
Kansas · 1
- The University of Kansas Cancer Center · Westwood, KS
Kentucky · 1
- University of Louisville · Louisville, KY
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- Weill Medical College of Cornell University · New York, NY
Ohio · 1
- University of Cincinnati · Cincinnati, OH
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.